Jasper Therapeutics
Logotype for Jasper Therapeutics Inc

Jasper Therapeutics (JSPR) investor relations material

Jasper Therapeutics Proxy filing summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Jasper Therapeutics Inc
Proxy filing summary19 Oct, 2026

Executive summary

  • Special meeting set for Nov. 13, 2026; seeks Nasdaq approval for conversion of merger and PIPE preferred stock, ratification of Patrick Crutcher’s board appointment, and authority to adjourn if needed.

  • Kira acquisition closed July 16, 2026; a private placement closed July 20, 2026, raising $132 million through preferred stock convertible into common shares.

  • Board recommends FOR all four proposals; merger itself and the merger agreement are not being submitted for a stockholder vote.

Voting matters and shareholder proposals

  • Merger conversion proposal seeks Nasdaq Rule 5635(a) and (b) approval for common shares issuable on conversion of merger preferred stock and exercise of Kira options; PIPE proposal seeks Rule 5635(d) approval for PIPE preferred conversion.

  • Each proposal requires a majority of shares present or represented by proxy and entitled to vote; abstentions count against, while broker non-votes do not affect the outcomes.

  • Proposal 3 asks stockholders to ratify Patrick Crutcher’s appointment; Proposal 4 would authorize adjournment to solicit more votes if support for Proposals 1–3 is insufficient.

  • Directors and officers agreed to vote shares representing ~1% of pre-transaction common stock FOR Proposals 1–3; the Board recommends FOR each proposal.

Board of directors and corporate governance

  • Patrick Crutcher joined the Board as a Class I director on July 16, 2026, as Kira’s designee; he also joined the Audit, Compensation, and Nominating and Corporate Governance committees.

  • Crutcher has 15+ years of biotechnology leadership and business development experience; his appointment remains effective if stockholders do not ratify it, though the Board will consider the vote in evaluating continued service.

  • Crutcher’s non-employee director terms include $40,000 annual cash compensation and a 15,000-share option grant, with 25% vesting after one year and the remainder monthly over 48 months, subject to continued service.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Jasper Therapeutics earnings date

Logotype for Jasper Therapeutics Inc
Q3 202620 Nov, 2026
Jasper Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Jasper Therapeutics earnings date

Logotype for Jasper Therapeutics Inc
Q3 202620 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutic agents primarily for hematopoietic stem cell transplantation and gene therapies. The company is focused on advancing novel therapeutic agents intended for a variety of applications, including conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes. Additionally, Jasper Therapeutics is developing new conditioning regimens for stem cell transplantation and ex-vivo gene therapy, which involves the genetic manipulation of cells outside the body before transplantation. Their leading product candidate, briquilimab, is designed to clear hematopoietic stem cells from bone marrow to facilitate allogeneic stem cell or gene therapy. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.